Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARALEN vs ARTESUNATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
Severe malaria (parenteral therapy),Uncomplicated malaria (combination therapy with other antimalarials),Off-label: Treatment of chloroquine-resistant falciparum malaria
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Primarily hydrolyzed in the stomach and in plasma by esterases to dihydroartemisinin (DHA), the active metabolite. DHA undergoes glucuronidation via UGT1A9 and UGT2B7.
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
Artemisinin derivatives: ~93% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Vd approximately 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in severe malaria due to increased capillary permeability.
Oral: 80-90%.
Oral: ~40% (range 20-50%) due to first-pass metabolism. Rectal: ~40-60%. IV: 100%.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
No dose adjustment required for any degree of renal impairment.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
No dose adjustment required for Child-Pugh A or B; caution in Child-Pugh C due to limited data.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
2.4 mg/kg IV at 0, 12, 24, and 48 hours; weight-based (minimum 2.4 mg/kg per dose).
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
No specific dose adjustment; use same dosing as adults with monitoring for adverse effects.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
None.
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
Hemolysis: Cases of delayed hemolytic anemia have been reported, especially in patients with high parasitemia.,Cardiotoxicity: Theoretical risk of QT prolongation with co-administration of other QT-prolonging drugs.,Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis) have occurred.
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Hypersensitivity to artesunate, any artemisinin derivative, or any component of the formulation.,Pregnancy: Not recommended in first trimester unless life-threatening; avoid in second/third trimester if safer alternatives available.,Breastfeeding: Safety not established; discontinue breast-feeding or avoid drug.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
No known significant food interactions. However, avoid grapefruit and grapefruit juice as they may alter drug metabolism (CYP2A6 inhibition). Maintain adequate hydration and nutrition to support recovery.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benefit of treating life-threatening malaria generally outweighs risks, as untreated malaria poses significant fetal risks. However, the drug should be used with caution and only when clearly needed.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
Artesunate is excreted into breast milk in small amounts. The M/P ratio is not well-established. While the American Academy of Pediatrics considers artesunate compatible with breastfeeding, caution is advised, especially in nursing preterm or jaundiced infants. The benefits of breastfeeding and the necessity of maternal treatment should be weighed.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
No dose adjustment is required for artesunate during pregnancy based on pharmacokinetic changes. However, intravenous artesunate is the recommended treatment for severe malaria in the second and third trimesters. Oral artesunate may be used for uncomplicated malaria, but caution is advised in the first trimester due to teratogenicity.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Artesunate is the first-line therapy for severe malaria (WHO recommendation). Administer IV or IM; IV dose is 2.4 mg/kg at 0, 12, and 24 hours then daily. Monitor for hypoglycemia and delayed hemolytic anemia (post-artesunate hemolysis). Not recommended for uncomplicated malaria due to risk of resistance. Artesunate is rapidly acting with a short half-life; always combine with a partner drug (e.g., artemether-lumefantrine) for complete cure. Do not use in first trimester of pregnancy unless life-threatening.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
Take this medication exactly as prescribed; do not stop early even if you feel better.,You may experience temporary side effects such as dizziness, nausea, or fatigue; report any severe reactions.,This drug is used for severe malaria; you will likely be hospitalized for close monitoring.,Watch for signs of low blood sugar (sweating, confusion, rapid heartbeat) and report immediately.,Inform your healthcare provider about all medications you are taking, especially blood thinners or anti-seizure drugs.,Complete the full course of treatment, including any follow-up medications to prevent recurrence.
No interactions on record
"Nicotine, a known inducer of cytochrome P450 (CYP) enzymes, particularly CYP1A2 and possibly CYP2A6, may increase the hepatic metabolism of artesunate to its active metabolite dihydroartemisinin. This enhanced clearance can lead to subtherapeutic plasma concentrations of dihydroartemisinin, reducing the antimalarial efficacy of artesunate and potentially increasing the risk of treatment failure and the development of drug resistance."
"Amiodarone, a potent CYP3A4 and CYP2B6 inhibitor, can significantly reduce the systemic exposure of dihydroartemisinin, the active metabolite of artesunate. This occurs through inhibition of cytochrome P450 enzymes responsible for the conversion of artesunate to its active form, leading to decreased antimalarial efficacy. Clinically, this interaction may result in treatment failure or recrudescence of malaria when artesunate is co-administered with amiodarone."
"The coadministration of buprenorphine, a partial mu-opioid receptor agonist, with artesunate may reduce the systemic exposure of dihydroartemisinin (DHA), the primary active metabolite of artesunate, thereby decreasing antimalarial efficacy. This interaction is believed to occur through buprenorphine-mediated induction of cytochrome P450 (CYP) enzymes responsible for artesunate metabolism, leading to enhanced clearance and subtherapeutic concentration of DHA. Clinically, this could result in delayed parasite clearance and increased risk of treatment failure in malaria patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARALEN vs ARTESUNATE, answered by our medical review team.
ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. ARTESUNATE is a Antimalarial that works by Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARALEN and ARTESUNATE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. The standard adult dose of ARTESUNATE is: 2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARALEN and ARTESUNATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. ARTESUNATE is classified as Category C. Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benef. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.